SNDX
Syndax Pharmaceuticals Inc
$22.89
-0.72 (-3.05%)
At close · Jul 13
Market Cap
$2.03B
Shares
88,610,027
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Michael A. Metzger | director | Appointed | 2026-06-10 |
| Pierre Legault | director | Appointed | 2026-06-10 |
Key facts
CIK
1395937
CUSIP
87164F105
13F (30d)
11 filings
10 filers
Visit website
Investor relations